RVL Pharmaceuticals plc Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2017 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
RVL Pharmaceuticals plc quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2017 to Q4 2022.
  • RVL Pharmaceuticals plc Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2022 was $64.9M, a 22.7% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2022 $64.9M +$12M +22.7% Dec 31, 2022 10-K 2023-03-20
Q4 2021 $52.9M +$25M +90% Dec 31, 2021 10-K 2023-03-20
Q4 2020 $27.8M +$6.6M +31.1% Dec 31, 2020 10-K 2022-03-30
Q4 2019 $21.2M +$20.9M +7019% Dec 31, 2019 8-K 2021-09-08
Q4 2018 $298K +$161K +117% Dec 31, 2018 10-K 2020-03-19
Q4 2017 $137K Dec 31, 2017 8-K 2019-12-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.